Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Carl Zeiss Meditec AG is a leading medical technology company specializing in ophthalmology and microsurgery solutions. Headquartered in Jena, Germany, and founded in 1846, it operates as a subsidiary of the ZEISS Group, delivering innovative products for diagnosing and treating eye diseases such as ametropia, cataracts, glaucoma, and retinal disorders. Its Ophthalmology segment provides diagnostic tools like slit lamps, refractometers, optical coherence tomography devices, and fundus cameras, alongside surgical equipment including microscopes, biometers, phacoemulsification systems, vitrectomy devices, intraocular lenses, and laser surgery consumables. The Microsurgery segment offers visualization and treatment solutions for neurosurgery, ear-nose-throat procedures, spine, plastic and reconstructive surgery, and dentistry. With a global presence across Europe, North America, and Asia, employing over 5,700 people, Carl Zeiss Meditec AG drives advancements in healthcare through cutting-edge technologies, digital workflow solutions, and AI-integrated systems, enhancing clinical efficiency and patient outcomes in advanced medical equipment sectors.
€29.90
+€0.60 (+2.05%)
EOD Aug 7, 2026
10.02% operating margin is respectable but not wide. ROIC at 7.34%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 7.8%, steady but not accelerating.
Even for strong businesses, today's 21x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
21.4x earnings, 13.9x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€2.20B
▲ +7.8% YoY
Net Income (TTM)
€122M
▼ -21.0% YoY
Op. Margin
8.91%
▲ +1.5pp YoY
ROIC
7.34%
▲ +1.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€176M
▲ +40.1% YoY
Op. Cash Flow (TTM)
€176M
▼ -27.2% YoY
Net Debt
€105M
Cash & Equiv.
€27M
3Y CAGR: +5.4%
3Y CAGR: +7.9%
Continue Research
At a P/E of 21.4 and a price-to-free-cash-flow of 13.9, Carl Zeiss Meditec (AFX.XETR) trades around a two-stage DCF intrinsic value of about €36.11 per share, so at €29.90 the stock looks around fair value (20.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Carl Zeiss Meditec scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 2.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €36.11 per share for AFX.XETR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €27.09. At today's €29.90, that puts the stock about 20.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Carl Zeiss Meditec scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 8.9% operating margin and a 7.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Carl Zeiss Meditec pays a regular dividend of about €0.64 per share per year (typically in quarterly installments), a yield of roughly 2.2% at the current price. That is a payout ratio of about 43.1% of earnings, so the dividend is well covered. Carl Zeiss Meditec has grown the dividend at roughly 4.1% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For AFX.XETR's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. AFX.XETR currently trades around its estimated intrinsic value and scores 60/100 on quality (solid). It also yields about 2.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.